anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses longan fructus lycii liquor which is prepared through conventional technologies from following components, by weight, 150 parts of longan pulp, 150 parts of fructus lycii, 60 parts of angelica sinensis, 25 parts of ginseng, 20 parts of white poria, 15 parts of fresh ginger, 20 parts of atractylodes macrocephala koidz and 1000 parts of liquor. The components, except the liquor, are placed in a container with addition of the liquor. The container is sealed and the components are soaked in the liquor for 15 days. Filtration is carried out to remove residues to obtain the longan fructus lycii liquor. The longan fructus lycii liquor has effects of nourishing blood and moistening skin and nourishing liver and kidney, is mainly used for treating poor health and pachulosis and ageing of skin and the like. The longan fructus lycii liquor is taken orally with a dosage being 10-20ml by two times per day.
The installation of a patch test for the cascara pulp cream of Gayo Arabica coffee with a concentration of 10% was carried out on the upper arm and waited for 30 minutes to see if there were any side effects. If no side effects occur, the patch test is left for 48 hours. After 48 hours, patch test was opened and the skin condition was assessed for irritation/redness and skin moisture. This condition was also re-evaluated at 72 and 96 hours later.
Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
Pharmaceutical compositions containing the polypeptides BUF-3, BUF-4 and BUF-5 have hypoglycemic activity. BUF-3 is a homodimer of monomer A shown in FIG. 1. The monomer has a molecular weight of 16±1 kd. BUF-4 is a heterodimer of monomer A and monomer B (FIG. 2). These products can be produced by cell culture of malignant leukemia cells or by recombinant DNA engineering.
The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
PURPOSE:To readily obtain the title factor in large quantities in high purity by incorporating a specific amino acid primary sequence. CONSTITUTION:A linked product prepared by linking DNA fragments formed by synthesizing e.g., single strand DNA of formula I is incorporated into vector pBR 322 to obtain vector pRE 125 (A) containing the DNA sequence of the gene coding the amino acid sequence of rabbit epithelial cell growth factor(EGF) of formula II. Thence, the component A is linked to plasmid pKTN to obtain EGF manifestation vector pRE 225 (B). The component B is then incorporated into Escherichia coli HB 101 strain to obtain vector-holding host cell (C). Thence, cells C is put to agitation culture at pH ca.6.7 and ca.35 deg.C for ca.17.5hr in a medium containing casamino acid, proline, etc., to obtain a cultured product (D). The product D is then purified through extraction, chromatography, etc., thus producing the objective rabbit epithelial cell growth factor having amino acid primary sequence of formula III.
Continuous Slow Activation Protocol: 2 activations of the expansion screw which is equal to 0,33 mm expansion of the maxilla per day during the first 7 days. After that first week, then each third day 1 activation (0,17 mm / 3 days).
Augmented renal clearance will be assessed in detail in a very large and heterogeneous adult critically ill population. Analysis will be conducted retrospectively on a multi-center database collected by the M@tric research group. M@tric collects data from all intensive care units (surgical, medical, cardiac) in 3 Belgian University Hospitals (Leuven, Ghent, Antwerp).

Anonymised admission, demographic, clinical and laboratory data collected from 2013 until the present will be retrieved from the M@tric database. These data will then be coded and analysed in R statistical software. ARC will be defined based on a 24h creatinine clearance (CrCl24h) \>=130ml/min/1.73m².

Epidemiology and risk factors for ARC will be studied in order to confirm and clarify past studies which have mostly been done in rather small and specific subsets of patients. A predictive algorithm for ARC will be trained and subsequently validated for use in clinical practice. Moreover this algorithm will be compared to existing scoring systems, which have not yet found their way into clinical practice. This algorithm will provide the ability to anticipate ARC on the intensive care unit. Also use of formulae estimating renal function will be evaluated in this population. These estimators will be compared to the CrCl24h, which is considered the golden standard in clinical practice. A cutoff for the best estimating formula in order to detect ARC will be calculated. Finally the impact of ARC on serum levels of hydrophilic molecules likes vancomycine and aminoglycosides will be studied. As this research follows a retrospective design these levels will be used a surrogate marker for clinical impact. This will potentially point out some opportunities for future research on the clinical impact of ARC.
Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement. In a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations. This correlation of disease progression with the modulation of the biomarkers suggest that GM604 can be used effectively in modulating ALS disease biomarkers, and consequently can be used for prognosis of ALS disease progression and therapeutic treatment to slow down ALS disease progression. The biomarker modulation can be a measure of drug efficacy.
PURPOSE:The titled cosmetic containing a condensate of an aromatic aldehyde with a specific sugaralcohol, a lower alkylene carbonate and/or an N-alkylpyrrolidone, an alcohol and a dye with little sagging or fading. CONSTITUTION:A solid cosmetic for hair dyeing containing four components of (A) a condensate of an aromatic aldehyde expressed by the formula (R is H, 1- 3C alkyl or 1-3C alkoxy) with a penta- or multivalent sugaralcohol at 2:1 molar ratio or a mixture of the condensate at 2:1 molar ratio with a condensate at 1:1 molar ratio, (B) a lower alkylene carbonate, e.g. ethylene carbonate, and/or an N-alkylpyrrolidone, e.g. N-methylpyrrolidone, (C) an alcohol and (D) a dye, e.g. Red No.2. The cosmetic is a solid and capable of dyeing the hair lightly without fear of dripping and has good dyeing ability of the hair with little staining of the hand or scalp.
The invention provides an article and a method for stimulating washing. In an optimal embodiment, the article comprises a substrate with a lower surface and an upper surface, and a soluble material layer covering the upper surface of the substrate and a final image, wherein the lower surface is suitable for effectively attaching the article to a user and the final image is positioned on the upper surface; and the soluble material layer is provided with a surfactant fully distributed on the surface. The soluble material layer comprises at least one initial image located on the soluble material layer. In use, the user moisturizes the soluble material layer and consumes the surfactant along the skin of the user by means of frictional force. In a use process, the soluble material layer and the initial image are dissolved until the user can see the final image. In the optimal embodiment of the invention, the final image is similar to a temporary tattoo.
Monitoring chronic diseases, particularly kidney disorders, in people living with HIV (PLWH) is of paramount importance. Here, a systematic search was conducted across electronic search engine and databases like PubMed, Scopus, and Google Scholar, from date of inception until December 2023, to identify pertinent studies reporting on any association between inflammation and kidney function in PLWH. Only six clinical studies in peer-reviewed journals met the inclusion criteria, involving 1467 participants aged 37 to 51, with approximately 17% being females. The report emphasizes the potential impact of highly active antiretroviral therapy (HAART) on kidney function in PLWH, highlighting the significance of monitoring inflammation markers as indicators of kidney function, even when HAART is effective. Acknowledging study limitations, particularly the scarcity of relevant research, the findings highlight a need for more research to inform on clinical guidance to optimize HIV management, particularly regarding kidney health and HAART regimens. Although very limited studies were evaluated, the study lays an important foundation for future research to uncover the complex relationship between HAART, inflammation markers, and kidney health in PLWH.
A process is disclosed which makes possible the isolation of the luminal endothelial cell membrane from associated tissue. It is particularly applicable to vasculature, but broadly is applicable to all tissue cavities which are accessible from adjacent perfusable lumens. The method involves the identification of characteristic molecules (primarily proteins and lipids) associated with the luminal surface of any endothelial membrane in situ by utilizing a novel membrane-isolation scheme to separate the endothelium from associated tissue. In this method, the endothelial luminal plasmalemma of a given organ is coated with colloidal silica by perfusion, a pellicle is formed, the coated area of tissue is excised and the coated plasmalemma fragments are isolated from cognate homogenate by centrifugation. The isolated plasmalemma attached to the pellicle can then be subjected to biochemical analysis to identify and catalogue molecules characteristic of the endothelial membrane. The method is broadly applicable to any tissue of any organ which is adjacent to a perfusable luminal cavity and which has luminal endothelial membrane exposed to such laminal cavity.
The invention relates to the field of traditional Chinese medicine preparations, in particular to a preparation method of a gardenia extract and a gardenia duodenum positioning preparation for treating cholestatic liver diseases. The preparation method of fructus Gardeniae extract comprises decocting fructus Gardeniae in water, passing the extractive solution through SP825L macroporous resin column at a speed of 2-4BV/h, collecting eluate, concentrating, and drying. The gardenia duodenal positioning preparation comprises a tablet core and an enteric coating wrapping the tablet core; the tablet core comprises fructus Gardeniae extract, lactose, microcrystalline cellulose and magnesium stearate; the enteric coating comprises No. I and No. II acrylic resin and diethyl phthalate. The active ingredients extracted by the preparation method are high in content, and the prepared gardenia duodenal positioning preparation is moderate in hardness, strong in moisture resistance, capable of rapidly disintegrating in duodenal fluid and being absorbed by organisms, and suitable for clinical emergencies such as cholestatic hepatitis and the like.
Abnormal macrophage polarization is one of the common pathological bases of various inflammatory diseases. The current research focus involves targeting macrophages to remodel their phenotype as a treatment approach for inflammatory diseases. Notably, exosomes can be delivered to specific types of cells or tissues or inflammatory area to realize targeted drug delivery. Although icariin (ICA) exhibits regulatory potential in macrophage polarization, the practical application of ICA is impeded by its water insolubility, poor permeability, and low bioavailability. Exploiting the inherent advantages of exosomes as natural drug carriers, we introduce a novel drug delivery system-adipose-derived stem cells-exosomes (ADSCs-EXO)-ICA. High-performance liquid chromatography analysis confirmed a loading rate of 92.7 ± 0.01 % for ADSCs-EXO-ICA, indicating the successful incorporation of ICA. As demonstrated by cell counting kit-8 assays, ADSCs-EXO exerted a significantly higher promotion effect on macrophage proliferation. The subsequent experimental results revealed the superior anti-inflammatory effect of ADSCs-EXO-ICA compared to individual treatments with EXO or ICA in the lipopolysaccharide + interferon-gamma-induced M1 inflammation model. Additionally, results from enzyme-linked immunosorbent assay, quantitative polymerase chain reaction, and western blot analyses revealed that ADSCs-EXO-ICA effectively inhibited macrophage polarization toward the M1-type and concurrently promoted polarization toward the M2-type. The underlying mechanism involved the modulation of macrophage polarization through inhibition of the Toll-like receptor 4/myeloid differentiation factor 88/nuclear transcription factor-kappa B signaling pathway, thereby mitigating inflammation. These findings underscore the potential therapeutic value of ADSCs-EXO-ICA as a novel intervention for inflammatory diseases.
The present invention relates to cosmetic composition, it is preferred for keratin fiber, such as, for the composition having hair dyed, it includes at least these components：A. (methylol) aminomethane；B. at least one amino acid；C. at least one organophosphorus compounds is selected from：C1. the phosphate monoester of alkoxy fatty alcohols, wherein the alkoxy fatty alcohols are constituted by with the fatty alcohols of 12 C of C 22 of 1 to 50 mol of alkylene oxide hydrocarbon alkoxylate, the molal quantity of the molal quantity relative to fatty alcohol of its alkylene oxide；C2. the diester of the phosphate of non-alkoxy fatty alcohols, wherein the non-alkoxy fatty alcohols are made up of the fatty alcohols of 12 C of C 22；With the mixture of c3.c1 and c2；D. water；Method the invention further relates to manufacture the dispersion comprising above-mentioned cosmetic composition；For the kit of two or more components of coloring keratin fibers；The instant composition as obtained by mix reagent box component；With the method for colouring the keratin fiber comprising the instant composition.
The present invention provides a novel lactobacillus strain separated from Kimchi. According to the present invention, a specific Bacillus sp. strain with high stability separated from Kimchi has various functions such as excellent anti-obesity activities, activities in lowering blood cholesterol, activities in lowering blood neutral lipid, or antioxidant activities, etc. Therefore, according to the present invention, the specific Bacillus sp. strain can be used as a useful food and drug ingredient for preventing, alleviating, or treating diseases such obesity, a fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular diseases, arteriosclerosis, and lipid-related metabolic syndrome. In addition, according to the present invention, a product fermented soybean, Codonopsis lanceolate, ginseng, and a Cornus officinalis seed with the specific Bacillus sp. strain and an extract thereof can be used as a useful food and drug ingredient for preventing, alleviating, or treating obesity or obesity-related diseases.
The present invention relates generally to data processing techniques for precisely acquiring dental CT images. In particular, the present invention relates to a series of data processing techniques for CT images, which detect a corner point from the outline of a binarized image for a series of two-dimensional CT data (slices) and perform corner region expansion through image segmentation to precisely extract a margin line from the dental CT image. According to the present invention, the method precisely acquires a margin line from a dental CT image, so that a prosthetic operation or an implant operation can be precisely performed, thereby providing advantages of increasing the success rate of prosthetic and implant operations and at the same time, reducing discomfort and pain of patients. In addition, the accuracy of data processing in the dental CT image is increased, thereby providing an advantage of expanding utilization of cone beam CT. In addition, a margin line can be acquired from the dental CT image only by software processing, thereby increase work efficiency and solving a conventional problem of varying the quality of a prosthesis according to individual ability of an operator. The method comprises the following steps: acquiring two-dimensional CT data; acquiring a binary image; detecting a tooth area; detecting an outline; detecting a corner point; acquiring an expanded corner area; and updating the binary image.
Participants will be given a daily prescription of metformin for 12 months postpartum. At 12 months and again at 15 months (3 months off the drug), HbA1c and weight will be assessed.
HPV 18 caused 19  percent of all cervical cancer cases in Sweden, in particular adenocarcinomas. High vaccination coverages are required to eliminate the most oncogenic HPV types like HPV 16 and HPV 18, while medium-oncogenic viruses such as HPV 31, 33, 45, 52, and 58 are easier to eliminate due to their lower reproduction number. Women born 1994-1998 were offered catch-up vaccination against HPV 16 and HPV 18 at ages 13-18, but only about 55 percent participated, which is insufficient to eliminate these viruses. Offering vaccination against HPV 16, 18, 31, 33, 45, 52, and 58 to women born in 1994-1998 and achieving around 70 percent participation should eliminate the medium-oncogenic viruses and achieve population immunity also for HPV 16/18. A national project offering free vaccines and screening against these HPV types is ongoing since 2021. Already at the start of the project, there was only a single case of HPV 18 in age groups with high vaccination coverage, implying that extinction of this virus is imminent.
The pilot maternal CVH intervention will be delivered by NFP partners starting as early as NFP program enrollment in the first trimester after confirmation of a viable pregnancy and no later than the 28th week of pregnancy and will continue up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long (weekly visits for the first month following enrollment followed by twice monthly visits until delivery). The pilot study will include an enhanced behavioral component target decreased sedentary time and increase physical activity and utilizing a technology/monitoring component. All women be monitored using a wrist-worn actigraphy device to record daily activity, intermittent home blood pressure self-monitoring, intermittent home weight self-monitoring, and carbon monoxide monitoring administered by the NFP nurse.
In the pre-feeding stage of the research, the parents of the preterms included in the sample will be met and informed about the research. Written and verbal consent will be obtained from parents who agreed to participate in the study. "Preterm Infants Information Form" will be filled by the researcher before feeding and "Feeding Monitoring Form" will be filled during feeding. By randomization, it will be determined which of the experimental and control groups the preterm infant will be assigned to. It will be ensured that the interventions that will affect the vital signs of the preterms in both groups before feeding are not applied. Oxygen saturation and heart rate will be monitored for 30 minutes before, during and after feeding for all groups. Preterms in both groups will be dressed in clean and dry diapers by cleaning their bottoms before feeding, and will be weighed naked with a digital baby scale by removing their clothes. Weighing the preterms with an electronic precision balance before and after feeding - the test weighing - will be used to measure the amount of milk the preterm is expressing from the breast or bottle. The preterm will then be fed loosely wrapped in a cotton blanket. If the oxygen saturation level of all preterm infants falls below 90% during feeding, it will be considered desaturated and the feeding will be stopped. The preterm infants will continue to be fed when the oxygen saturation is ≥ 90% and the heart rate is 120-160/min. Feeding will be limited to a total of 30 minutes for infants in both groups, including rest intervals, and will not take longer. When the feeding is complete, preterms in both groups will be weighed naked without changing the diaper under the feeding process. It will be ensured that interventions that may affect the vital signs of all preterms included in the study are not applied when feeding is completed. The oxygen saturation and heart rate of the preterms in both groups will be monitored for 30 minutes after the feeding is completed. When feeding is complete, preterms in both groups will be placed on the same mother's breast in the right lateral position to facilitate gastric emptying.
Introduction Visual hallucinations occur frequently in Parkinson's disease (PD). The prevalence of visual hallucinations ranges from 22 to 38%, increasing after long-term follow-up to more than 60%. Risk factors for visual hallucinations are age, disease duration, and cognitive impairment. The treatment of visual hallucinations is cumbersome and options are limited. Only clozapine has been proven to be efficacious without deteriorating the motor symptoms of PD. Instead of oral dopamine agonists and rotigotine, continuous infusion of apomorphine is well-tolerated in PD patients with cognitive impairments and/or visual hallucinations. Even beneficial effect of apomorphine on visual hallucinations are suggested, however there is lack of a randomized controlled trial.

The purpose of this randomised, double-blind, placebo-controlled trial is to evaluate the efficacy of continuous apomorphine infusion compared to placebo in PD patients with visual hallucinations, inadequately controlled with clozapine and cholinesterase inhibitors.